Table 1 Off-label use of tocilizumab (TCZ) in pediatric patients with Takayasu arteritis
Authors, year (ref.) | Sex | Age at onset, years | Age at TCZ, years | Manifestations | Previous therapy | Dose of TCZ | Duration of TCZ, months | Adverse effect of TCZ | Â |
|---|---|---|---|---|---|---|---|---|---|
Bravo Mancheno et al., 2012 [38] | F | 3 | 5 | Wall thickening, occlusion | GC, MTX, ETN, IFX, CYC, MMF | 8 mg/kg /2–3 weeks | > 24 | No | |
Batu et al., 2017 [39] | F | 4 | 9 | Stenosis | GC, CYC, MTX, AZA | 8 mg/kg /4 weeks | 7–13 | No |  |
F | 13 | 15 | Aneurysms | ||||||
F | 16 | 16 | Graft, stenosis and aneurysms | GC, CYC, MTX | |||||
GC, CYC, ETN | |||||||||
F | 16 | 16 | Wall thickening | GC | |||||
Decker et al., 2018 [40] | F | 13 | 15 | Panaortitis | GC, MTX, IFX | 8 mg/kg /4 weeks | 18 | No |  |
Canas et al., 2014 [41] | F | 12 |  | Wall thickening | GC | 8 mg/kg /4 weeks | 18 | No |  |
F | 14 | Wall thickening | GC, MTX | 12 | |||||
Goel et al., 2013 [42] | F | 13 | 13 | In-stent restenosis | GC, MMF | 8 mg/kg /4 weeks | 6 | No serious AE |  |
In-stent restenosis | GC, MMF | ||||||||
F | 14 | 15 | |||||||